anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Foam cells in atheroma are engorged with lipid droplets (LDs) that contain esters of regulatory lipids whose metabolism remains poorly understood. LD-associated hydrolase (LDAH) has a lipase structure and high affinity for LDs of foam cells. Using knockout and transgenic mice of both sexes, here we show that LDAH inhibits atherosclerosis development and promotes stable lesion architectures. Broad and targeted lipidomic analyzes of primary macrophages and comparative lipid profiling of atheroma identified a broad impact of LDAH on esterified sterols, including natural liver X receptor (LXR) sterol ligands. Transcriptomic analyzes coupled with rescue experiments show that LDAH modulates the expression of prototypical LXR targets and leads macrophages to a less inflammatory phenotype with a profibrotic gene signature. These studies underscore the role of LDs as reservoirs and metabolic hubs of bioactive lipids, and suggest that LDAH favorably modulates macrophage activation and protects against atherosclerosis via lipolytic mobilization of regulatory sterols.
INTRODUCTION: The article focuses on the professional quality of life of medical residents, and specifically on compassion fatigue and compassion satisfaction. Previous studies have indicated high levels of emotional stress among residents. Most of these studies were conducted within the positivistic paradigm. The qualitative study concentrates on pediatric residents during ER rotations in both routine and pandemic times.
AIMS: The research goal is to explore how compassion fatigue and compassion satisfaction are manifested among the residents.
METHODS: Conducted in the phenomenological genre, the study included 14 pediatric residents in a large Israeli hospital. The research tool was a semi-structured interview.
RESULTS: All residents reported substantial work overloads. About half of the participants indicated signs of compassion fatigue, manifested in negative emotions and diminished empathy and sensitivity, especially towards patients' families. Some exhibited a combination of compassion fatigue and compassion satisfaction. About half of the residents clearly expressed feelings of compassion satisfaction or empathy for patients (without direct expressions of compassion satisfaction).
CONCLUSIONS: The research gave pediatric residents a platform to express their voices, shedding light on the complexity of their work. While a substantial number of participants reported compassion fatigue, the findings are encouraging. Despite the reported work overload, most of them maintained their sense of commitment and compassion, which are crucial for their work. However, participants' senses of stress and burnout have negative consequences both individually and organizationally. The study suggests that residents might gain from systematic intervention and recommendations have been offered to hospital administrations.
Participants in Arm 2 will be posted the Under \& Over study pack (2) and asked to complete the Under \& Over tool daily for as long or short as they choose or are able to. They will be asked to complete 5 days per week for 3 months. They will be instructed to follow the instruction booklet in any order they wish, choosing which pattern they would like to complete. They will also be encouraged to create their own patterns. These participants will have access to a section of the study website where they will be able to upload photographs of their patterns and see other participants' patterns over the 3-month period.
767,266. Frequency measurement. ELLIOTT BROS. (LONDON), Ltd. June 15, 1955 [March 15, 1954], No. 7524/54. Class 37. An instrument for checking or measuring the frequency of an A.C. source comprises a dynamometer instrument whose moving coil is energized from the source through a series impedance such that the current therein leads the supply voltage, and whose fixed coil is energized through a series impedance such that the current lags the voltage; the impedance magnitudes being variable and calibrated in response to frequency so that at the frequency to be checked or measured the sum of the phase angles between the coil currents and the source voltage is 90 degrees and the deflection of the instrument is zero. Moving coil M of the instrument is energized from the source TT through series variable resistance R2 shunted by capacitance C, while fixed coil F is energized through series resistance R1 and inductance L. Corresponding currents I1 lagging the supply voltage by 61 and I2 leading it by 62 flow in the coils, and when #1 + #2 = 90 degrees deflection is zero so that the impedances may be proportioned for zero deflection at the source frequency whose correct value is to be checked. #1 and . 62 may be 45 degrees so that deviations are symmetrically indicated. Resistance R2 may be continuously variable and calibrated in source frequency while inductance L and capacitance C may be simultaneously-variable in steps by a ganged switch calibrated in discrete frequency ranges ; the frequency being indicated when the resistance and impedances are adjusted to zero deflection of the instrument, which may be of the kind described in Specification 765,682 incorporating switching to introduce the required variable impedance components in series with the fixed and moving coils across the source.
The embodiments herein relate to a system and method for detecting an internal object (100) in a body under test (103). The system comprises at least one antenna (105) which are adapted to be positioned around the body under test (103). The system is adapted to transmit radio frequency signal(s) into the body under test (103) which are reflected and/or scattered from the internal object (103). The system is adapted to receive the reflected and/or scattered radio frequency signal(s) and use a method of classification S1-S7 to determine the presence of an internal object (100). The system is adapted to detect the internal object (100) or a change in an already detected internal object (100) when there is a difference between the received radio frequency signals. The difference is related to the different dielectric properties between the internal object (100) and the body under test (103).
The acknowledged drugs of choice for the pharmacological treatment of insomnia are the benzodiazepine receptor agonist hypnotics (BzRA). Studies show that at therapeutic doses, used over the short-term, the abuse liability of BzRAs is relatively low and their efficacy outweighs their minimal risks. However, an increasing number of patients use BzRAs nightly for longer periods of time than is currently indicated (i.e. 4 weeks) and, minimal data on the long-term abuse liability and efficacy of these drugs exist.

This project, using both prospective and retrospective methods, will address questions about the long-term abuse liability and efficacy of the BzRAs. The questions being raised are: What are the abuse liability and efficacy of hypnotics currently being used chronically and what is the prospective abuse liability and efficacy of hypnotics used chronically? Zolpidem is the chosen standard for this project as it is the most frequently prescribed BzRA and also arguably the BzRA with the best short-term efficacy and safety profile. The focus of the first question is clinical; it is about the long-term abuse liability and efficacy of BzRAs, specifically zolpidem, as it is currently being prescribed and about the type of patients who receive this drug. The second question addresses the issue of whether a standard BzRA can be prescribed efficaciously and safely for the long-term to patients with primary insomnia.
Moderate-late preterm-born infants experience more frequent and severe respiratory tract infections and wheezing compared to term-born infants. Decreasing the risk on respiratory tract infections and wheezing in this group is vital to improve quality of life and reduce medical consumption during infancy, but also to reduce the risk on asthma and COPD later in life. Until now, moderate-late preterm infants are underrepresented in research and mechanisms underlying their morbidity are largely unknown, although they represent 80% of all preterm-born infants. In order to protect these infants effectively, it is essential to understand the role of the immune system in early life respiratory health and to identify strategies to optimize immune development and respiratory health. This review elaborates on risk factors and preventative measures concerning respiratory tract infections and wheezing in preterm-born infants, exploring their impact on the immune system and microbiome. Factors discussed are early life antibiotic use, birth mode, feeding type and living environment. Further, differences in adaptive and innate immune maturation between term and preterm infants are discussed, as well as differences in local immune reactions in the lungs. Finally, preventative strategies are being explored, including microbiota transplantation, immune modulation (through pre-, pro-, syn- and postbiotics, bacterial lysates, vaccinations, and monoclonal antibodies) and antibiotic prophylaxis.
PURPOSE: A production method of a panaxadiol saponin strengthened fraction of ginseng or red ginseng is provided to conduct the ultrafiltration of ginseng or red ginseng for obtaining more than 5 content ratio of panaxadiol for panaxatriol. CONSTITUTION: Dried ginseng or red ginseng is extracted by using an extraction solvent. The extract is concentrated. The obtained concentrate is mixed with 3-20 times the amount of water for diluting, and the ultrafiltration is conducted with the mixture based on the molecular weight of 2,000-3,500. The extraction is conducted by using 3-20 times the amount of water, C1-4 low class alcohol, or their mixture at 50-80°C for 18-24 hours. A panaxadiol saponin strengthened fraction of the ginseng or red ginseng has the content ratio of ginsenoside Rb1 for ginsenoside Rg1 of 15-150. [Reference numerals] (AA) Example 1; (BB) Example 2; (CC) Example 3
A breakfast consisting of whole slices of refined wheat bread containing 50 g of available carbohydrates. The breakfast additionally included 250 mL water and 50 g of cucumber.
A 30-year-old man who received infliximab for treatment of Crohn's disease developed Epstein-Barr virus (EBV) encephalitis, which responded well to therapy; however, he had left lower visual field loss following treatment. The patient noticed peculiar symptoms 9 months after recovery from encephalitis; objects in his view appeared smaller or larger than their actual size (micropsia/macropsia). Moreover, it appeared that objects outside moved faster or slower than their actual speed of movements and moving objects appeared as a series of many consecutive snap shots. His vision was blurred, and he had visual difficulties and a sensation that his body was floating. These symptoms mainly appeared following fatigue and persisted over approximately 10 years. Based on cerebrospinal fluid analysis, brain MRI, N-isopropyl-p-123I-iodoamphetamine with single photon emission computed tomography, fluorodeoxyglucose positron emission tomography, and electroencephalography, we excluded both recurrent encephalitis and focal epileptic seizures. By taking all symptoms and other evaluation findings into account, the patient most likely suffered from "Alice in Wonderland syndrome" which is primarily associated with cortical dysfunction in the right temporo-parieto-occipital area as the consequence of previous acute EBV encephalitis.
The invention discloses application of pyridine-piperazine compounds to prepare anti-HIV-1 medicines. The general formula of the compounds is shown in the specification. In the general formula, a piperazine-containing group is at No. 1 or No. 2 position, and R is independently a C1-C5 chain hydrocarbon or a C4-C6 cyclohydrocarbon. By utilizing the interaction of Vif-APOBEC3G, the compounds with the above general formula, especially (4-cyclopentylpiperazin-1-yl)(pyridin-2-yl)methanone is confirmed to be capable of inhibiting the activity of Vif protein on degrading A3G and leading rising up of expression level of green fluorescent protein in a screening system. By performing wild-type HIV-1 infection experiments on human primary CD4+T lymphocyte and H9, SupT1 and other CD4+T lymphocytic series, (4-cyclopentylpiperazin-1-yl)(pyridin-2-yl)methanone is further confirmed to have relatively good antiviral effect. A powerful theoretical basis and a practice basis are provided for further research and development of antiviral medicines, and the compounds have important value on research and development and exploitation meaning.
Methods of delivering a cargo moiety to a cell is provided according to embodiments of the present invention which includes contacting a cell expressing sialoadhesin with a conjugate including a sialoadhesin binding moiety and a cargo moiety. The sialoadhesin binding moiety binds to the sialoadhesin expressed by the cell and is internalized along with the cargo, delivering the cargo moiety to the cell. Particular methods provided by the present invention include induction or enhancement of sialoadhesin expression in a cell which naturally produces little or no sialoadhesin. Induction or enhancement of sialoadhesin expression includes transfection of a sialoadhesin expression construct and/or administration of an agent effective to induce or enhance sialoadhesin expression. Methods and compositions for stimulating an immune response in a subject are detailed. Particular methods and compositions for stimulating an immune response to a virus are provided by the present invention.
DOSAGE MUST BE INDIVIDUALIZED AND CLOSELY MONITORED BY A PHYSICIAN DURING UP-TITRATION. Prior to initiation of COREG, it is recommended that fluid retention be minimized. The recommended starting dose of COREG is 3.125 mg twice daily for 2 weeks. If tolerated, patients may have their dose increased to 6.25, 12.5, and 25 mg twice daily over successive intervals of at least 2 weeks. Patients should be maintained on lower doses if higher doses are not tolerated. A maximum dose of 50 mg twice daily has been administered to patients with mild-to-moderate heart failure weighing over 85 kg (187 lbs).

Patients should be advised that initiation of treatment and (to a lesser extent) dosage increases may be associated with transient symptoms of dizziness or lightheadedness (and rarely syncope) within the first hour after dosing. During these periods, patients should avoid situations such as driving or hazardous tasks, where symptoms could result in injury. Vasodilatory symptoms often do not require treatment, but it may be useful to separate the time of dosing of COREG from that of the ACE inhibitor or to reduce temporarily the dose of the ACE inhibitor. The dose of COREG should not be increased until symptoms of worsening heart failure or vasodilation have been stabilized.

Fluid retention (with or without transient worsening heart failure symptoms) should be treated by an increase in the dose of diuretics.

The dose of COREG should be reduced if patients experience bradycardia (heart rate <55 beats/minute).

Episodes of dizziness or fluid retention during initiation of COREG can generally be managed without discontinuation of treatment and do not preclude subsequent successful titration of, or a favorable response to, carvedilol.
The invention relates to a traditional Chinese medicine formula for preventing and treating bird flu. The formula comprises Andrographis paniculata, honeysuckle, Mahonia fortunei, screwtree root, herba houttuyniae, dendranthema indicum, cyperus rotundus, gleditsia sinensis, realgar, medicated leaven, brucea javanica, folium eriobotryae, garlic, alum, liquor, vinegar and sodium bicarbonate. The components are mixed uniformly according to a certain proportion and are mixed with a feed. After being used for feeding chickens for 3-4 days, the feed can prevent and treat bird flu well. An experiment proves that a preventing effect can reach more than 90% and a curative ratio can reach more than 95%. Economic loss due to a large-scale outbreak of the bird flu can be reduced and benefits of farmers can be maximumly protected.
BACKGROUNDS: The internal fixation for rib fracture with single-operation-port (two ports) complete video-assisted thoracoscopic surgery (VATS) is a promising surgical approach for treating multiple rib fractures. The study aimed to investigate the minimally invasive surgical procedure's clinical effect in treating multiple rib fractures.
METHODS: Seventy-three patients with multiple rib fractures were divided into two groups according to surgical procedure. In the study group, 42 patients were operated on with the internal fixation of rib fracture with single-operation-port complete VATS. In the control group, this study performed the open operative internal fixation for rib fracture with traditional thoracotomy on 31 patients. The surgical-related indexes were retrospectively analyzed. These included the operative time, the intraoperative blood loss, the drainage amount of the chest tube, the placement time of the chest tube, the postoperative hospital stay, the incidence of postoperative complications, the imaging efficacy of rib fixation of rib fractures, and visual analog scale of pain scoring (VAS scoring).
RESULTS: There was no difference in the operative time between the study and control groups (P = 0.806). The intraoperative blood loss, the chest tube drainage amount, the chest tube placement time, the postoperative hospital stay, and the incidence of postoperative complications in the study group were lower than those in the control group (P < 0.05). There was no significant difference in the imaging efficacy of rib fixation of rib fractures between the two groups (P = 0.806). VAS scores in the study group on the seventh postoperative day were significantly reduced compared with the control group (P = 0.026).
CONCLUSION: The internal fixation for rib fractures with single-operation-port complete VATS is a feasible, safe, simple, and minimally invasive surgical procedure to treat multiple rib fractures, which is worthy of clinical application.
44 adults (aged between 18 and 65) with acute (\< 6 weeks) unilateral symptomatic RC tendinopathy will be recruited.This single-blind (assessor), parallel-group RCT will include three evaluation sessions over 6 weeks (baseline, week 2, week 6) and one meeting with the treating physiotherapist (right after the baseline evaluation). All participants will take part in the baseline evaluation. They will first complete a questionnaire on sociodemographic, symptomatology and comorbidity, as well as self-administered questionnaires that evaluate symptoms and functional limitations (DASH, WORC and BPI). Then, ultrasonographic (US) measurements of AHD and of the supraspinatus tendon and subacromial bursal thickness will be conducted. Thereafter, pain inhibitory control will be assessed using conditioned pain modulation. Finally, the corticospinal excitability of the infraspinatus muscle will be evaluated. Thereafter, participants will be randomly assigned to one of two intervention groups, and then take part in their assigned home program. At week 2 and 6, the self-administered questionnaires will be re-administered (by phone for the week 6 evaluation). A global rating of change question (with % of change since baseline) will also be completed at week 2 and 6. US measurements, conditioned pain modulation and corticospinal excitability will only be revaluated at week 2. To evaluate the effectiveness of blinding, the assessor will complete a question related to his/her opinion of the allocation at week 2. The study will be carried out at the Centre interdisciplinaire de recherche en réadaptation et en intégration sociale (CIRRIS) by two different physiotherapists and in two different laboratories. Ethics approval will be obtained from Institutional Review Board of IRDPQ.
Epinephrine Injection, USP 1:1000 is a sterile, nonpyrogenic solution. Each mL contains epinephrine 1 mg; sodium chloride 9 mg; sodium metabisulfite 0.9 mg added. May contain hydrochloric acid for pH adjustment.

The solution contains no bacteriostat or antimicrobial agent. It is administered by the following routes: intravenous, intracardiac (left ventricular chamber), via endotracheal tube into the bronchial tree, subcutaneous or intramuscular. 

Epinephrine, USP is a sympathomimetic (adrenergic) agent designated chemically as 4‑[1‑hydroxy-2 (methylamino) ethyl]-1,2 benzenediol, a white, microcrystalline powder. It has the following structural formula:

Sodium Chloride, USP is chemically designated NaCl, a white, crystalline compound freely soluble in water.
This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I. The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
Cannabidiol-C4 (CBD-C4, nor-cannabidiol) for use as a medicament is provided. CBD-C4 may be in the form of a plant extract, preferably in the form of a highly purified plant extract. The plant extract may comprise at least 95% (w/w) CBD-C4. CBD-C4 may be in the form of a synthetic compound. A composition for use comprising CBD-C4 and one or more pharmaceutically acceptable excipients is provided. Cannabidiol-C4 for use in the treatment of epilepsy is provided. A process for the preparation of cannabidiol-C4 is provided.
The active ingredient in gabapentin tablets, USP is gabapentin USP which has the chemical name 1-(aminomethyl)cyclohexaneacetic acid.

The molecular formula of gabapentin is C9H17NO2 and the molecular weight is 171.24. The structural formula of gabapentin is: 

Gabapentin, USP is a white to off-white powder with a pKa1 of 3.7 and a pKa2 of 10.7. It is freely soluble in water, 0.1 N hydrochloric acid, 0.1 N sodium hydroxide and glacial acetic acid; slightly soluble in methanol, very slightly soluble in ethanol, 2-propanol; insoluble in toluene. The log of the partition coefficient (n-octanol/0.05M phosphate buffer) at pH 7.4 is –1.25. 

Each gabapentin tablet, USP intended for oral administration contains 600 mg and 800 mg of gabapentin. In addition each tablet contains following inactive ingredients: copovidone, low substituted hydroxypropyl cellulose, magnesium stearate, mannitol, poloxamer, povidone and talc.